玉森新药“双喜临门”：两款1.1类中药新药获临床许可

Core Insights - Suzhou Yusen Pharmaceutical Co., Ltd. has achieved significant milestones in new drug development, particularly in traditional Chinese medicine innovation [1][2] - The company has received clinical trial approval for its innovative traditional Chinese medicine, Xiaoxian Zhihuan Oral Liquid, aimed at treating children with adenoid hypertrophy [1] - Yusen Pharmaceutical has also collaborated with Shandong Hanfang Pharmaceutical Co., Ltd. to develop a new drug, Pediatric Liuwei Eczema Gel, which has received clinical implied permission [2] Group 1 - Yusen Pharmaceutical focuses on modernizing traditional Chinese medicine and has developed a complete innovation system from drug discovery to industrialization [1] - The company has addressed key challenges in pediatric medication, such as taste, low drug loading, and product stability, through technological innovations [1] - The Xiaoxian Zhihuan Oral Liquid is the first traditional Chinese medicine for children with clear theoretical support, good taste, and stable quality [1] Group 2 - The Pediatric Liuwei Eczema Gel targets eczema, a common skin disease with a prevalence rate of 2%-10% in adults and 15%-30% in children in China [2] - The unique characteristics of eczema in children necessitate the development of effective, safe, and low-recurrence medications [2] - Yusen Pharmaceutical aims to accelerate the product launch of Pediatric Liuwei Eczema Gel to benefit children suffering from eczema [2]